Deal Roundup: Carlyle, CVC strike €1bn BauWatch deal, HIG agrees $866m Mistras take-private

Carlyle and CVC DIF to acquire 90% of BauWatch for €1bn, with Haniel retaining 10%. HIG Capital to take Mistras Group private for $866m, or $20.35 per share. Searchlight Capital to finance $1.6bn take-private of Priority Technology at $8.05 per share. Peugeot Invest invests $175m in Mérieux NutriSciences. Thrive Capital distributes 6.3m Oscar Health shares to LPs. Rainmaker raises $100m Series B. Generate Capital sells 12 anaerobic digestion sites.

Original reporting
Published Sep 22, 2026, 2:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MG
Relevance
9/10
AlphAI data visualization · based on altassets.net
Decision brief

The 30-second read

High
01

Why it matters

These deals represent significant capital deployment and ownership shifts, offering immediate trading opportunities around deal announcements.

02

Market read

M&A announcements drive short‑term price moves; investors should monitor deal completion milestones.

03

What to watch

Regulatory approvals for the Mistras take‑private and potential antitrust scrutiny in health‑tech.

Relevance 9/10Novelty 9/10Timing: today

Background

The article aggregates several newly announced private‑equity and strategic transactions across Europe and the US.

Market effects

Private‑equity activity signals continued consolidation in industrial testing and health‑tech sectors.

European security market sees new private‑equity backing; US health‑tech faces higher insider ownership.

Large‑scale M&A deals influence global capital allocation trends across technology and industrial sectors.

Counterpoint

Deal premiums may be overstated; post‑close integration risks could depress long‑term returns.

Key entities

  • HIG Capital

    Acquirer of Mistras Group.

  • Thrive Capital

    Distributor of Oscar Health shares to its LPs.

Related articles

MedAI 9/10

Mistras agrees $866 million sale to H.I.G. Capital

Mistras Group has agreed to be acquired by H.I.G. Capital for $20.35 per share, with an enterprise value of $866 million. The deal, approved by the board, is expected to close in late 2026 or early 2027, pending shareholder and regulatory approvals. Mistras provides industrial inspection services, and the acquisition price represents an 8-13% premium over recent share prices.

$MGHighAI 9/10

H.I.G. Agreed to Acquire MISTRAS Group for $20.35 Per Share:

MISTRAS Group (MG) agreed to be acquired by H.I.G. Capital for $20.35 per share in cash, implying an enterprise value of $866 million including debt. The deal represents an 8% and 13% premium over 30-day and 90-day average prices. The MISTRAS board approved the transaction, which is expected to close in late 2026 or early 2027, subject to approvals and a 40-day go-shop period.

$MGHighAI 8/10

MISTRAS Group, Inc. Enters into Definitive Agreement to Be Acquired by H.I.G. Capital for $20.35 Per Share in Cash

MISTRAS Group (MG) agreed to be acquired by H.I.G. Capital for $20.35 per share, representing an 8% and 13% premium over 30- and 90-day averages, respectively. The deal values the company at $866M, including debt. The transaction is expected to close in late 2026 or early 2027, subject to shareholder and regulatory approvals. MG's stock will delist upon completion.

$MGMedAI 9/10

Mistras Group (MG) Q2 2026 Earnings Call Transcript

Mistras Group (MG) reported Q2 2026 revenue of $193.1 million, up 4.2% YoY, and record adjusted EBITDA of $25.8 million with a 13.3% margin. GAAP net income was $7.6 million. The company raised 2026 guidance to $740-$755 million revenue and $92-$95 million adjusted EBITDA, citing growth in aerospace, infrastructure, and power.